ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn's disease <li /> New detailed data from ...
Hosted on MSN11m
Johnson & Johnson’s TREMFYA® Shows Promising Results in Ulcerative Colitis PatientsJohnson & Johnson (NYSE: JNJ) has announced positive results from the Phase 3 ASTRO study evaluating TREMFYA® (guselkumab) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback